North America Digital Pathology Market: Disease Diagnosis Application Segment Of Digital Pathology Is Anticipated To Exhibit The Fastest Growth
North America Digital Pathology Industry Overview
The North America digital pathology market size is expected to reach USD 593.9 million by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.5% from 2021 to 2028. The market is predominantly driven by the growing prevalence of chronic diseases such as cancer. As a consequence of the high prevalence of cancer, pathologists require data that facilitate personalizing therapy for patients. Hence, digital pathology is progressively being selected by pathologists as it has various benefits including accelerated diagnosis rate, diagnostic accuracy, and offers therapeutic recommendations to improve patient outcomes.
The growing number of collaborative agreements to develop as well as expedite the adoption of digital pathology in cancer diagnostics serves as a key growth factor contributing to the market. The use of artificial intelligence in digital pathology has gained momentum in the past years. The increasing need for lowering healthcare costs, increasing importance of big data in healthcare, rising adoption of precision medicine, and declining hardware costs are some factors driving the growth. In addition, increasing usage of artificial intelligence-based analytical tools in healthcare and high capital investments in this field are further propelling the market growth.
During the coronavirus outbreak, the exponential need for home-based workstations and safe clinical informatics systems allowing healthcare professionals to read images remotely and enabling virtual collaboration between their multi-disciplinary care teams has increased. Various histopathology departments in the region faced a reducing workforce and increasing workload during the pandemic. Digital pathology considered being the potential solution for some of the challenges faced by the pathologist, there is an increase in the adoption of digital diagnosis of disease during coronavirus outbreak.
In April 2020, Philips announced that the FDA granted a waiver for home use of consumer monitors with the company's IntelliSite Pathology Solution during the emergency. The temporary exemption of restrictions on remote use of the digital pathology helps pathologists to access whole slide images from home and fasten the diagnosis of histology cases. Some pathology labs that have adopted DP in their workflows across different sites pre-COVID-19, reported improved collaboration, and an average productivity gain of 21.0% with operation efficiency increased by 13.0%. These types of initiatives are anticipated to fuel market growth.
North America Digital Pathology Market Segmentation
Grand View Research has segmented the North America digital pathology market on the basis of the product, application, end use, and country:
Based on the Product Insights, the market is segmented into Software, and Device.
- The device segment dominated the market and accounted for the largest revenue share of 52.0% in 2020. The devices include scanners, clinical-grade computers, and slide management systems. Increasing adoption for academic and research activities and enhanced resolution are the key factors driving the growth of the segment.
- Digital pathology also allows the sharing of information for publication and research, diagnostics, and education through the internet. Thus, it reduces the sharing costs. Traditionally, to achieve accurate tumor diagnosis results, multiple tests had to be carried out, which are drastically reduced by a single test performed by a digital pathology system.
Based on the Application Insights, the market is segmented into Drug Discovery & Development, Academic Research, and Disease Diagnosis.
- The academic research segment dominated the market and accounted for the largest revenue share of 46.0% in 2020. The disease diagnosis segment accounted for a revenue share of 46.0% in 2020. The growth of the academic research segment can be attributed to factors such as an increase in the adoption of digital pathology in various research studies including tumor morphological and biomarker profiling.
- The disease diagnosis application segment of digital pathology is anticipated to exhibit the fastest growth. An increasing number of activities by public and private organizations such as the American Society for Clinical Pathology (ASCP) and College of American Pathologists (CAP), which are focused on improving the quality of cancer diagnosis is presenting lucrative growth opportunities.
Based on the End-use Insights, the market is segmented into Cancer Hospitals, Diagnostic Labs, and Academic & Research Institutes.
- Digital pathology is predominantly used by research institutes, educational institutes, and veterinary pathologists. Academic medical centers, commercial labs, and large independent pathology labs were initial adopters of digital pathology systems. The high penetration in research institutes is due to the high adoption of digital pathology in oncology clinical trials, preclinical GLP pathology, and drug discovery and development.
- Hospitals are implementing digital scanners for rapid diagnosis and better outcomes. As of now, it is anticipated to play a critical role in diagnostics as the FDA approved the digital pathology systems for primary diagnosis, further widening its growth potential. Rising cancer prevalence and high demand for better diagnostic and treatment options are further contributing towards the growth.
Key Companies Profile & Market Share Insights
The industry is expected to remain innovation-led, with frequent acquisitions and strategic alliances. Application development along with competent distribution channels will be key for competitive advantage. Leading companies are focusing on strategies such as collaborations, new product developments, research agreements, and mergers and acquisitions to gain a competitive advantage. For instance, in July 2020, Paige, a computational pathology player, received the U.S. FDA 510(k) clearance for the FullFocus, digital pathology image viewer for primary diagnosis. The clearance allowed in vitro diagnostic (IVD) use of FullFocus in conjugation with Philips Ultra-Fast Scanner.
Moreover, in April 2020, FDA approved Sectra's digital pathology module for primary diagnostics. Before this module is only used for research in the U.S. This module can be used in conjunction with the AT2 DX scanner provided by Leica Biosystem. This will intensify the competition in the market as previously the market is dominated by Philips. Some of the prominent market players in the North America digital pathology market include:
- Leica Biosystems
- Hamamatsu Photonics, Inc.
- Koninklijke Philips N.V.
- Hoffmann-La Roche Ltd
- Mikroscan Technologies
- 3DHISTECH Ltd.
- Inspirata, Inc.
- Visiopharm A/S
- Huron Technologies International, Inc.
- Sectra AB
Order a free sample PDF of the North America Digital Pathology Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Comments
Post a Comment